BAX - Baxter International Inc Stock Price, Fair Value and News

39.67USD+0.15 (+0.38%)Market Closed

Market Summary

USD39.67+0.15

Market Closed

0.38%

BAX Stock Price

View Fullscreen

BAX RSI Chart

BAX Valuation

Market Cap

20.1B

Price/Earnings (Trailing)

7.58

Price/Sales (Trailing)

1.36

EV/EBITDA

37.64

Price/Free Cashflow

11.67

BAX Price/Sales (Trailing)

BAX Profitability

EBT Margin

-0.51%

Return on Equity

31.61%

Return on Assets

9.39%

Free Cashflow Yield

8.57%

BAX Fundamentals

BAX Revenue

Revenue (TTM)

14.8B

Rev. Growth (Yr)

3.74%

Rev. Growth (Qtr)

4.77%

BAX Earnings

Earnings (TTM)

2.7B

Earnings Growth (Yr)

35.36%

Earnings Growth (Qtr)

-90.23%

Breaking Down BAX Revenue

Last 7 days

-5.9%

Last 30 days

-4.9%

Last 90 days

1.8%

Trailing 12 Months

-7.7%

How does BAX drawdown profile look like?

BAX Financial Health

Current Ratio

1.48

Debt/Equity

1.32

Debt/Cashflow

0.16

BAX Investor Care

Dividend Yield

1.63%

Dividend/Share (TTM)

0.67

Shares Dilution (1Y)

0.63%

Diluted EPS (TTM)

5.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.5B	14.6B	14.7B	14.8B
2022	12.8B	13.3B	13.6B	14.5B
2021	11.8B	12.2B	12.5B	12.1B
2020	11.5B	11.4B	11.5B	11.7B
2019	11.0B	11.1B	11.2B	11.4B
2018	10.8B	11.0B	11.0B	11.1B
2017	10.3B	10.3B	10.4B	10.6B
2016	9.9B	10.1B	10.1B	10.2B
2015	10.6B	10.4B	10.2B	10.0B
2014	14.1B	13.3B	12.3B	10.7B
2013	14.2B	14.2B	14.4B	15.0B
2012	14.0B	14.0B	14.0B	14.2B
2011	13.2B	13.5B	13.8B	13.9B
2010	12.7B	12.7B	12.8B	12.8B
2009	12.3B	12.2B	12.2B	12.6B
2008	0	11.6B	12.0B	12.3B
2007	0	0	0	11.3B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Baxter International Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	rosenbloom david s.	acquired	-	-	53,584	evp and general counsel
Mar 06, 2024	borzi james w	acquired	-	-	33,341	evp,chief supply chain officer
Mar 06, 2024	almeida jose e	acquired	-	-	142,891	chairman, ceo, president
Mar 06, 2024	knight heather	acquired	-	-	107,168	evp,group pres,med products
Mar 06, 2024	toth christopher a.	acquired	-	-	119,076	evp,group pres, kidney care
Mar 06, 2024	grade joel t.	acquired	-	-	42,867	evp and cfo
Mar 06, 2024	rasul reazur	acquired	-	-	83,353	evp,group pres, healthcare
Mar 06, 2024	stevens brian	acquired	-	-	14,289	svp, cao & controller
Mar 06, 2024	mason jeanne k	acquired	-	-	47,630	evp, chief hr officer
Mar 06, 2024	sonig alok	acquired	-	-	83,353	evp,group president, pharma

Which funds bought or sold BAX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	added	10.62	1,242,000	2,261,000	0.08%
Apr 17, 2024	Symphony Financial, Ltd. Co.	sold off	-100	-245,959	-	-%
Apr 17, 2024	ROMANO BROTHERS AND COMPANY	reduced	-1.04	156,488	1,821,540	0.25%
Apr 17, 2024	PEOPLES FINANCIAL SERVICES CORP.	reduced	-13.04	-3,435	85,460	0.04%
Apr 17, 2024	JEPPSON WEALTH MANAGEMENT, LLC	new	-	211,819	211,819	0.08%
Apr 17, 2024	Private Ocean, LLC	unchanged	-	943	9,873	-%
Apr 17, 2024	GUIDANCE CAPITAL, INC	new	-	870,426	870,426	0.32%
Apr 17, 2024	Kathleen S. Wright Associates Inc.	unchanged	-	408	4,274	-%
Apr 17, 2024	HARTFORD INVESTMENT MANAGEMENT CO	reduced	-3.78	84,089	1,402,900	0.05%
Apr 17, 2024	Baker Ellis Asset Management LLC	added	3.13	542,703	4,415,470	0.66%

Are Funds Buying or Selling BAX?

Are funds buying BAX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BAX

No. of Funds

Unveiling Baxter International Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	dodge & cox	5.4%	27,381,465	SC 13G
Feb 13, 2024	vanguard group inc	11.86%	60,155,132	SC 13G/A
Jan 23, 2024	blackrock inc.	11.8%	59,678,841	SC 13G/A
May 09, 2023	morgan stanley	0.6%	3,186,104	SC 13G/A
Apr 10, 2023	wellington management group llp	0.11%	559,390	SC 13G/A
Apr 10, 2023	vanguard group inc	12.03%	60,794,820	SC 13G/A
Feb 09, 2023	vanguard group inc	9.86%	49,705,350	SC 13G/A
Feb 08, 2023	morgan stanley	5.5%	27,835,167	SC 13G/A
Feb 06, 2023	wellington management group llp	7.16%	36,104,233	SC 13G/A
Jan 06, 2023	blackrock inc.	10.0%	50,522,292	SC 13G/A

Recent SEC filings of Baxter International Inc

View All Filings

Date Filed	Form Type	Document
Mar 27, 2024	DEFA14A	DEFA14A
Mar 25, 2024	DEF 14A	DEF 14A
Mar 25, 2024	DEFA14A	DEFA14A
Mar 21, 2024	8-K	Current Report
Mar 14, 2024	PRE 14A	PRE 14A
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to Baxter International Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.1B	-5.83%	1.66%	31.91	4.55	-8.12%	-17.45%
BDX	67.4B	19.5B	-2.32%	-8.43%	53.63	3.46	4.02%	-22.04%
ALGN	22.6B	3.9B	-4.99%	-13.70%	50.88	5.86	3.42%	23.09%
BAX	20.1B	14.8B	-4.86%	-7.71%	7.58	1.36	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.64%	16.68%	32.29	2.63	4.97%	18.89%
HSIC	9.0B	12.3B	-5.34%	-15.09%	21.61	0.73	-2.44%	-22.68%
BIO	8.2B	2.7B	-12.68%	-39.24%	-12.88	3.07	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.94%	-25.15%	-46.91	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-1.55%	17.10%	-563.48	9.33	33.86%	89.83%
PDCO	2.3B	6.6B	-3.92%	-2.28%	11.8	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-5.32%	-19.06%	-1.84	0.39	7.73%	-1066.14%
ANIK	378.4M	166.7M	1.82%	-7.51%	-4.58	2.27	6.67%	-456.34%
ANGO	245.1M	324.0M	17.44%	-27.90%	-1.27	0.76	-3.19%	-337.41%
APYX	47.5M	52.3M	-25.42%	-56.00%	-2.54	0.91	17.61%	19.28%
AEMD	3.7M	3.7M	-14.97%	255.00%	-0.31	1	5.77%	8.23%

Baxter International Inc News

Latest updates

Baxter International Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	4.8%	3,885	3,708	3,707	3,513	3,745	3,609	3,594	3,558	2,876	3,226	3,098	2,946	3,181	2,972	2,718	2,802	3,039	2,851	2,834	2,638	2,833
Gross Profit	31.8%	1,472	1,117	1,111	1,275	1,388	1,045	1,371	1,262	1,021	1,321	1,233	1,145	1,191	1,195	1,038	1,163	1,298	1,230	1,153	1,080	1,183
S&GA Expenses	-2.4%	978	1,002	964	1,010	899	941	970	1,052	863	680	675	627	650	601	590	628	666	627	641	601	627
R&D Expenses	3.6%	172	166	165	164	154	151	148	150	135	129	139	128	135	123	117	146	156	144	166	129	175
EBITDA Margin	20.0%	0.05*	0.04*	-0.13*	-0.10*	-0.09*	-0.10*	0.14*	0.15*	0.17*	0.17*	0.17*	0.17*	-	-	-	-	-	-	-	-	-
Interest Expenses	43.0%	-73.00	-128	-124	-117	-117	-104	-89.00	-85.00	-75.00	-50.00	-34.00	-34.00	-38.00	-39.00	-36.00	-21.00	-20.00	-13.00	-20.00	-18.00	-11.00
Income Taxes	171.5%	160	-223	10.00	25.00	11.00	-54.00	34.00	21.00	-58.00	-1.00	91.00	51.00	39.00	56.00	42.00	45.00	-204	106	13.00	44.00	102
Earnings Before Taxes	222.1%	210	-172	-183	70.00	122	-3,045	219	94.00	-78.00	451	392	351	210	415	289	378	-223	481	326	386	413
EBT Margin	54.4%	-0.01*	-0.01*	-0.19*	-0.16*	-0.16*	-0.17*	0.07*	0.09*	0.12*	0.11*	0.11*	0.11*	-	-	-	-	-	-	-	-	-
Net Income	-90.2%	245	2,508	-141	44.00	181	-2,937	252	71.00	238	450	298	298	168	356	246	332	-23.00	369	313	342	305
Net Income Margin	1.5%	0.18*	0.18*	-0.19*	-0.17*	-0.17*	-0.16*	0.07*	0.08*	0.10*	0.10*	0.09*	0.09*	-	-	-	-	-	-	-	-	-
Free Cashflow	45.5%	531	365	351	479	439	290	274	208	693	675	477	377	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.8%	28,276	30,656	27,885	28,291	28,287	27,965	31,831	32,716	33,521	19,807	19,682	19,466	20,019	20,098	19,465	19,075	18,193	17,299	17,503	16,241	15,720
Current Assets	-20.2%	9,600	12,034	8,205	8,099	8,011	7,810	7,882	8,173	8,872	8,167	8,004	7,856	8,411	9,033	8,566	8,333	7,503	7,210	7,229	6,060	5,959
Cash Equivalents	-44.8%	3,194	5,788	1,722	1,673	1,718	1,601	1,852	2,294	2,951	3,258	3,136	3,182	3,736	4,359	4,085	4,110	3,335	3,009	2,934	1,902	1,838
Inventory	-1.7%	2,824	2,873	2,897	2,922	2,679	2,675	2,663	2,548	2,453	2,025	2,065	2,017	1,916	1,988	1,905	1,694	1,653	1,715	1,756	1,743	1,667
Net PPE	3.6%	4,433	4,278	4,494	5,000	4,695	4,799	4,976	5,114	5,178	4,582	4,649	4,614	4,722	4,460	4,382	4,340	4,512	4,406	4,485	4,476	4,530
Goodwill	1.7%	6,514	6,407	6,418	6,868	6,452	6,639	9,644	9,816	9,418	3,098	3,148	1.00	3,217	3,094	3,052	2,961	3,030	2,847	2,937	-	-
Liabilities	-11.9%	19,808	22,490	22,254	22,350	22,392	22,386	22,928	23,597	24,400	10,992	11,147	10,976	11,293	11,496	11,305	11,345	10,281	9,682	9,700	8,648	7,854
Current Liabilities	4.7%	6,503	6,209	5,765	4,760	4,745	3,708	3,916	3,890	4,236	3,441	3,344	3,187	3,333	3,422	2,880	3,036	3,230	2,611	2,557	3,276	2,814
Short Term Borrowings	-100.0%	-	514	249	50.00	299	275	200	200	301	301	51.00	-	-	-	1.00	221	226	-	2.00	796	2.00
Long Term Debt	-20.9%	11,130	14,067	14,306	15,278	15,232	16,153	-	-	17,149	-	-	-	-	-	-	-	4,809	-	5,157	3,451	3,481
Shareholder's Equity	3.7%	8,402	8,101	5,631	5,941	5,833	5,579	8,903	9,119	9,121	8,815	8,535	8,490	8,726	8,602	8,160	7,730	7,912	7,617	7,803	7,593	7,866
Retained Earnings	0.6%	16,114	16,015	13,655	13,947	14,050	14,015	17,099	16,994	17,065	16,967	16,658	16,502	16,328	16,285	16,055	15,935	15,718	15,849	15,598	15,414	15,075
Additional Paid-In Capital	0.3%	6,389	6,368	6,341	6,312	6,322	6,297	6,253	6,207	6,197	6,131	6,090	6,043	6,043	6,009	5,975	5,935	5,955	5,926	5,906	5,839	5,898
Shares Outstanding	-0.2%	506	507	506	505	504	503	503	503	502	500	503	505	-	-	-	-	-	-	-	-	-
Minority Interest	1.5%	66.00	65.00	62.00	62.00	62.00	44.00	44.00	44.00	44.00	45.00	41.00	38.00	37.00	35.00	32.00	31.00	30.00	29.00	24.00	23.00	22.00
Float	-	-	-	23,000	-	-	-	32,000	-	-	-	40,000	-	-	-	44,000	-	-	-	42,000	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	45.5%	531	365	351	479	439	290	274	208	693	675	477	377	712	510	374	272	829	701	446	128	709
Share Based Compensation	-26.8%	30.00	41.00	37.00	25.00	31.00	45.00	45.00	32.00	53.00	34.00	37.00	22.00	33.00	33.00	35.00	29.00	30.00	35.00	35.00	22.00	28.00
Cashflow From Investing	-106.1%	-230	3,786	-173	-170	-256	-184	-187	-304	-10,267	-207	-188	-538	-264	-157	-154	-604	-421	-231	-147	-301	-216
Cashflow From Financing	-4633.9%	-2,935	-62.00	-120	-372	-119	-302	-469	-548	9,276	-324	-349	-358	-1,143	-111	-261	1,170	-116	-354	730	238	-1,508
Dividend Payments	0%	147	147	146	146	146	146	141	140	140	141	124	125	125	125	112	111	113	112	97.00	101	102
Buy Backs	-	-	-	-	-	-	32.00	-	-	-	35.00	312	253	500	-	-	-	241	309	123	597	1,424

BAX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 14,813,000,000	$ 14,506,000,000	$ 12,146,000,000
Cost of sales	9,838,000,000	9,440,000,000	7,426,000,000
Gross margin	4,975,000,000	5,066,000,000	4,720,000,000
Selling, general and administrative expenses	3,946,000,000	3,859,000,000	2,845,000,000
Research and development expenses	667,000,000	602,000,000	531,000,000
Goodwill impairments	0	2,812,000,000	0
Other operating expense (income), net	(28,000,000)	36,000,000	(6,000,000)
Operating income (loss)	390,000,000	(2,243,000,000)	1,350,000,000
Interest expense, net	442,000,000	395,000,000	193,000,000
Other (income) expense, net	51,000,000	12,000,000	41,000,000
Income (loss) from continuing operations before income taxes	(103,000,000)	(2,650,000,000)	1,116,000,000
Income tax (benefit) expense	(34,000,000)	4,000,000	83,000,000
Income (loss) from continuing operations	(69,000,000)	(2,654,000,000)	1,033,000,000
Income from discontinued operations, net of tax	2,732,000,000	233,000,000	262,000,000
Net income (loss)	2,663,000,000	(2,421,000,000)	1,295,000,000
Net income attributable to noncontrolling interests	7,000,000	12,000,000	11,000,000
Net income (loss) attributable to Baxter stockholders	$ 2,656,000,000	$ (2,433,000,000)	$ 1,284,000,000
Income (loss) from continuing operations per common share
Basic (in dollars per share)	$ (0.15)	$ (5.29)	$ 2.04
Diluted (in dollars per share)	(0.15)	(5.29)	2.01
Income from discontinued operations per common share
Basic (in dollars per share)	5.40	0.46	0.52
Diluted (in dollars per share)	5.40	0.46	0.52
Net Income (loss) per common share
Basic (in dollars per share)	5.25	(4.83)	2.56
Diluted (in dollars per share)	$ 5.25	$ (4.83)	$ 2.53
Weighted-average number of shares outstanding
Basic (in shares)	506	504	502
Diluted (in shares)	506	504	508

BAX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,194	$ 1,718
Accounts receivable, net of allowance of $129 in 2023 and $114 in 2022	2,690	2,571
Inventories	2,824	2,679
Prepaid expenses and other current assets	892	857
Current assets of discontinued operations	0	186
Total current assets	9,600	8,011
Property, plant and equipment, net	4,433	4,695
Goodwill	6,514	6,452
Other intangible assets	6,079	6,793
Operating lease right-of-use assets	524	541
Other non-current assets	1,126	1,109
Non-current assets of discontinued operations	0	686
Total assets	28,276	28,287
Current liabilities:
Short-term debt	0	299
Current maturities of long-term debt and finance lease obligations	2,668	1,105
Accounts payable	1,241	1,110
Accrued expenses and other current liabilities	2,594	2,170
Current liabilities of discontinued operations	0	61
Total current liabilities	6,503	4,745
Long-term debt and finance lease obligations	11,130	15,232
Operating lease liabilities	438	447
Other non-current liabilities	1,737	1,848
Non-current liabilities of discontinued operations	0	120
Total liabilities	19,808	22,392
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2023 and 2022	683	683
Common stock in treasury, at cost, 175,861,893 shares in 2023 and 179,062,594 shares in 2022	(11,230)	(11,389)
Additional contributed capital	6,389	6,322
Retained earnings	16,114	14,050
Accumulated other comprehensive income (loss)	(3,554)	(3,833)
Total Baxter stockholders’ equity	8,402	5,833
Noncontrolling interests	66	62
Total equity	8,468	5,895
Total liabilities and equity	$ 28,276	$ 28,287

About Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.

CEO	Mr. Jose E. Almeida
WEBSITE	baxter.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	60000

Baxter International Inc Frequently Asked Questions

What is the ticker symbol for Baxter International Inc? What does BAX stand for in stocks?

BAX is the stock ticker symbol of Baxter International Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Baxter International Inc (BAX)?

As of Wed Apr 17 2024, market cap of Baxter International Inc is 20.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BAX stock?

You can check BAX's fair value in chart for subscribers.

What is the fair value of BAX stock?

You can check BAX's fair value in chart for subscribers. The fair value of Baxter International Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Baxter International Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Baxter International Inc a good stock to buy?

The fair value guage provides a quick view whether BAX is over valued or under valued. Whether Baxter International Inc is cheap or expensive depends on the assumptions which impact Baxter International Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BAX.

What is Baxter International Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, BAX's PE ratio (Price to Earnings) is 7.56 and Price to Sales (PS) ratio is 1.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BAX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Baxter International Inc's stock?

In the past 10 years, Baxter International Inc has provided 0.013 (multiply by 100 for percentage) rate of return.